Target intelligence / Profile preview

Bacterial adhesion to mucous membranes

Molecular classification
Other
01

Overview

Bacterial adhesion to mucous membranes refers to the initial step in many infections, where bacteria attach to the mucus that coats epithelial surfaces (e.g., respiratory, gastrointestinal, or genitourinary tracts)[1][5][3]. This step is primarily mediated by bacterial surface structures, including **adhesins** (such as fimbriae/pili, outer membrane proteins, or surface polysaccharides), which interact with specific or non-specific components of the mucus layer or underlying epithelial cells[4][5][1]. In respiratory and other mucosae, chronic infection and disease often depend on the pathogen’s ability to remain adherent in the face of mucus clearance and immune defenses[1][7]. Interference with this process is a validated anti-infective strategy, evidenced by the development of **FimH antagonists** for uropathogenic Escherichia coli, and by research targeting pili or mucin interactions to limit colonization[2][7][5]. While critical in infection biology, "bacterial adhesion to mucous membranes" does not describe a single standardized, druggable protein target, but instead a process involving various bacterial structures and host factors. If you require information about specific adhesin molecules (such as FimH, P pili, or other defined adhesins), those should be considered individual molecular targets (e.g., "FimH adhesin" or "Toxin coregulated pilus"), rather than the general phenomenon of adhesion[4][5][7].

Other names
Bacterial adherence to mucosaBacterial attachment to mucusBacterial-mucosal adhesion
02

Mechanism of action

Inhibition of adhesion proteins (e.g., blocking FimH); Disruption of pili/fimbriae; Blocking host receptor sites; Modifying mucin properties

03

Biological functions

ColonizationVirulenceInfection initiationImmune evasion
04

Disease associations

InfectionOther
05

Safety considerations

Non-specific effects on microbiotaPotential interference with normal protective microbiotaPossible disruption of beneficial mucosal barriers
06

Interacting drugs

FimH antagonists (e.g., mannosides)

3 more in the full profile.

Beyond the preview

Go deeper on Bacterial adhesion to mucous membranes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial adhesion to mucous membranes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call